Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral OKN-007 in Recurrent High-Grade Glioma
NCT03649464Phase 2Withdrawn
- Sponsor
- Oblato, Inc.
- Start
- Aug 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of OKN-007 in glioblastoma (GBM), astrocytoma, Oligodendroglioma (OG), sponsored by Oblato, Inc.. Planned start Aug 2022; status: withdrawn.
02
Drugs
OKN-007
03
Conditions
glioblastoma (GBM)astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on NCT03649464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03649464.